February 2024: American Academy of Allergy, Asthma, and Immunology
Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema
December 2023: World Allergy Congress
Support for STAR-0215 Administered Every Three- or Six-Months for Hereditary Angioedema: Phase 1a Results
November 2023: American College of Allergy, Asthma, and Immunology
Support for STAR-0215 Administered Every Three- or Six-Months for Hereditary Angioedema: Phase 1a Results
July 2023: Hereditary Angioedema Association National Summit
People Living with Hereditary Angioedema (HAE) Prioritize Attack-Free Status as Target for Therapeutic Efficacy
June 2023: European Academy of Allergy and Clinical Immunology Annual Congress
STAR-0215 Bound to Active Plasma Kallikrein Structure Uncovers a New Binding Mode
June 2023: European Academy of Allergy and Clinical Immunology Annual Congress
Design of a Phase 1b/2 Proof-of-Concept Trial of STAR-0215 as a Long-Acting Preventative Therapy in Patients with Hereditary Angioedema (HAE) Types I or II
June 2023: European Academy of Allergy and Clinical Immunology Annual Congress
Initial Results from a Phase 1a Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema (HAE), in Healthy Adult Subjects Followed for 3 Months
May 2023: 13th C1-Inhibitor Deficiency and Angioedema Workshop
Design of ALPHA-STAR, a Phase 1b/2 proof-of-concept trial of STAR-0215 as a long-acting preventative therapy in patients with hereditary angioedema (HAE) Types I or II
May 2023: 13th C1-Inhibitor Deficiency and Angioedema Workshop
Mechanistic Modeling and Simulations Predict Long-Term HAE Attack Prevention with STAR-0215
February 2023: AAAAI Annual Meeting
Structure of STAR-0215 Bound to Active Plasma Kallikrein Reveals a Novel Mechanism of Enzyme Inhibition
